ijms-logo

Journal Browser

Journal Browser

Special Issue "Nano-Strategies: The Future Medicine for Fighting Cancer Progression and Drug Resistance 2.0"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: 30 September 2021.

Special Issue Editor

Dr. Giovanni L. Beretta
E-Mail Website
Guest Editor
Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy
Interests: cancer research; cancer chemotherapy; molecular biology; cell biology; pharmacology; nanomedicine; drug discovery
Special Issues and Collections in MDPI journals

Special Issue Information

Dear colleagues,

The administration of conventional antitumor therapy is the first choice in clinical practice for patients suffering from disseminated tumors. Unfortunately, the development of drug resistance and systemic toxicity often require the suspension of treatment and lead to tumor progression and patients’ deaths. Among the several strategies considered to counteract drug resistance, the encapsulation of the drugs into nanovectors appears very promising. Importantly, their capability demonstrated in protecting cargo makes nanodevices useful for the delivery of therapeutic nucleic acids, a field of research that has increased significantly in recent years. Despite numerous studies that have proved the efficacy of nanosystems in (i) carrying a large therapeutics “payload,” (ii) accommodating multiple drug molecules that simultaneously enable combinatorial cancer therapy and bypass well-known drug resistance mechanisms, and (iii) targeting specific cells/tissues through the multivalent targeting ligands, which yield high affinity and specificity, only a limited number of nanodevices have attained clinical success (e.g., Doxil and Abraxane). These features imply that additional efforts are required before nanomedicine supplants conventional drug delivery administration. In this Special Issue, we welcome contributions, reviews, and original articles focused on all the aspects embraced by nanostrategies and adopted for combating cancer progression and drug resistance.

Dr. Giovanni L. Beretta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer
  • Antitumor drugs
  • Nanomedicine
  • Tumor progression
  • Metastasis
  • Drug resistance
  • Biomarkers
  • Drug delivery
  • Pharmacology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue
Int. J. Mol. Sci. 2021, 22(9), 4673; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094673 - 28 Apr 2021
Viewed by 368
Abstract
Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for cancer relapse is the development of multidrug resistance (MDR) hampering the treatment and prognosis. [...] Read more.
Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for cancer relapse is the development of multidrug resistance (MDR) hampering the treatment and prognosis. MDR can occur due to a multitude of molecular events, including increased expression of efflux transporters such as P-gp, BCRP, or MRP1; epithelial to mesenchymal transition; and resistance development in breast cancer stem cells. Excessive dose dumping in chemotherapy can cause intrinsic anti-cancer MDR to appear prior to chemotherapy and after the treatment. Hence, novel targeted nanomedicines encapsulating chemotherapeutics and gene therapy products may assist to overcome cancer drug resistance. Targeted nanomedicines offer innovative strategies to overcome the limitations of conventional chemotherapy while permitting enhanced selectivity to cancer cells. Targeted nanotheranostics permit targeted drug release, precise breast cancer diagnosis, and importantly, the ability to overcome MDR. The article discusses various nanomedicines designed to selectively target breast cancer, triple negative breast cancer, and breast cancer stem cells. In addition, the review discusses recent approaches, including combination nanoparticles (NPs), theranostic NPs, and stimuli sensitive or “smart” NPs. Recent innovations in microRNA NPs and personalized medicine NPs are also discussed. Future perspective research for complex targeted and multi-stage responsive nanomedicines for metastatic breast cancer is discussed. Full article
Show Figures

Graphical abstract

Open AccessReview
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
Int. J. Mol. Sci. 2020, 21(17), 6018; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176018 - 21 Aug 2020
Cited by 2 | Viewed by 790
Abstract
Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop [...] Read more.
Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision. Full article
Show Figures

Figure 1

Back to TopTop